Fig. 1

Schematic view of equipment; not to scale







Fig. 2

Side views of test stage; not to scale







Top view of test stage; not to scale








b)



c)



Carbamylcholine Response (1 mM, five spots)




Figure 6

Carbamylcholine Response (1 mM, five spots)




Figure 7

FCCP Response (50 µM, 5 x 5 grid of spots)





Figure 8

Call The Act and the Act and the first first

65. 65. 479 (P) PP (P) 10. 5. 5. 5.






Figure 9

FCCP Dose-response (50, 5, 0.5, 0.05 and 0.005 μM, 5 x 5 grid)




Figure 10

FCCP Dose-response (50, 5, 0.5, 0.05 and 0.005 μ M)




Figure 11

Ionomycin and Thapsigargin responses




Figure 12

Ionomycin and Thapsigargin responses (mean of two to three responses)




Figure 13